Early Detection of Nephrotoxicity
Unanticipated toxicity profiles and side effects plague new drug candidates, causing huge research investment losses. Metabolon’s technology is uniquely positioned to accelerate MOA, identify biomarkers of toxicity, understand toxicity mechanisms, further personalized medicine and tailor therapy approaches.
Approximately 30% of new drug candidates fail in clinical trials due to unanticipated toxicity profiles1. Current nephrotoxicity tests are either invasive and difficult to measure or noninvasive and imprecise and none are capable of early nephrotoxicity detection.